Trigeminal neuralgia is a debilitating chronic neuropathy characterized by sudden, short and intense episodes of shooting, stabbing or shock-like pain in the face. To date, there is still an incomplete understanding of the pathophysiologic molecular mechanisms behind trigeminal neuralgia and the search for molecular targets is of medical need.
Seelos Therapeutics has been selected to receive a grant from The Michael J. Fox Foundation (MJFF) for Parkinson's Research to advance preclinical research and development of its gene therapy delivered SLS-004 program.
Noninvasive electrical stimulation of the brain for 20 minutes per session over 4 days has been demonstrated to improve both working- and long-term memory for at least 1 month, in people aged 65-88 years.
Because dysregulated energy metabolism is common across both familial and sporadic forms of amyotrophic lateral sclerosis (ALS), targeting energy production is believed to have therapeutic potential. University of Edinburgh and University of Oxford researchers have tested modulating the expression of the glycolysis enzyme phosphoglycerate kinase 1 (PGK1) in preclinical models of ALS by using terazosin, a PGK1 activator, with the aim of confirming it as a therapeutic target in the treatment of the disease.
Parkinson's disease (PD) is the second most common neurodegenerative disorder and is characterized by the progressive loss of dopaminergic neurons in the substantia nigra and the abnormal accumulation and aggregation of alpha-synuclein.
Valentine’s Day is a great day for creating that tingly feeling, but Abbott Park, Ill.-based Abbott Laboratories believes that this is not a good sensation for patients who are in search of pain relief via spinal cord stimulation (SCS) devices. Thus, the company touts its Proclaim Plus as a system that delivers a tightly titrated charge to multiple sites on the spinal cord to generate an analgesic effect without that tingling sensation, an outcome the company said is preferred by 87% of those in need of SCS for pain relief.
Noninvasive electrical stimulation of the brain for 20 minutes per session over four days has been demonstrated to improve both working- and long-term memory for at least one month, in people ages 65 to 88.
China Hinye Pharmaceutical has presented new phenol derivatives acting as GABA(A) receptor alpha1beta2gamma2S positive allosteric modulators (PAMs) reported to be useful for the treatment of anxiety disorders, convulsions, migraine, nausea and vomiting and neurodegeneration.
XtalPi has discovered heterocyclic amide derivatives acting as prostaglandin E2 receptor EP4 subtype (PTGER4; EP4) antagonists reported to be useful for the treatment of pain, rheumatoid arthritis, osteoarthritis and cancer.